Botanix Pharmaceuticals Ltd (BOT:ASX)


right-arrow Created with Sketch. -0.002 (-3.17%)
MCAP $61.30M
Last trade 15.05pm 28/10/2021 20mins delayed

Latest Announcements

26/10/2021BOTBotanix Pharmaceuticals Ltd
26/10/2021BOTBotanix Pharmaceuticals Ltd
25/10/2021 Price SensitivePSBOTBotanix Pharmaceuticals Ltd
08/10/2021BOTBotanix Pharmaceuticals Ltd
29/09/2021 Price SensitivePSBOTBotanix Pharmaceuticals Ltd
24/09/2021BOTBotanix Pharmaceuticals Ltd
20/09/2021BOTBotanix Pharmaceuticals Ltd
20/09/2021BOTBotanix Pharmaceuticals Ltd

Company Overview

Botanix Pharmaceuticals Limited is a clinical-stage synthetic cannabinoid pharmaceutical company focuses on the development of dermatology and antimicrobial products. The Company's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The Company also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT in the news

Botanix Pharmaceuticals (BOT) has continued progressing multiple clinical programs over the September…
Botanix Pharmaceuticals (BOT) launches a canine atopic dermatitis program following ethics approvalThe…
Botanix Pharmaceuticals (BOT) reports a net loss after tax of $3.33 million…
Botanix Pharmaceuticals (BOT) opens red on the ASX following the release of…

Search Previous Announcements